Pernix Therapeutics Holdings Inc (PTX) was Downgraded by Brean Capital to ” Hold”. Earlier the firm had a rating of “Buy ” on the company shares. Brean Capital advised their investors in a research report released on Aug 12, 2016.
Pernix Therapeutics Holdings Inc opened for trading at $0.778 and hit $0.7799 on the upside on Monday, eventually ending the session at $0.751, with a gain of 1.21% or 0.009 points. The heightened volatility saw the trading volume jump to 32,31,378 shares. Company has a market cap of $46 M.
In a different news, on Aug 20, 2015, Barry J Siegel (Senior VP and General Counsel) purchased 5,000 shares at $4.49 per share price. According to the SEC, on Aug 19, 2015, Sanjay S Patel (CFO) purchased 5,000 shares at $4.60 per share price. On Aug 19, 2015, Douglas Drysdale (CEO) purchased 8,500 shares at $4.69 per share price, according to the Form-4 filing with the securities and exchange commission.
Pernix Therapeutics Holdings Inc. (Pernix) is a pharmaceutical company. The Company is engaged in the acquisition development and commercialization of prescription drugs primarily for the United States market. The Company focuses on underserved therapeutic areas such as central nervous system (CNS) including neurology and psychiatry as well as other specialty therapeutic areas. The Company’s products include Treximet an analgesic indicated for acute migraine; Silenor (doxepin) a prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance and Khedezla (desvenlafaxine extended-release tablets) for major depressive disorder. The Company distributes its generic products through wholly owned subsidiaries Macoven Pharmaceuticals LLC (Macoven) and Cypress Pharmaceuticals Inc. (Cypress).